News Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer Staff September 11, 2023 Iframe sync Post Navigation Previous EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023Next Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference More Stories Healthcare News Pharmaceutical Define Ventures Appoints Carolyn Magill as Venture Partner Staff March 11, 2025 Healthcare News So-Young to Report Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 Staff March 11, 2025 News Robotics AMI and congatec Celebrate 20 Years of Successful Partnership Staff March 11, 2025
